Ultimovacs ASA Secures Prospectus Approval for Business Growth

Author: Olivia Taylor Updated: 02-28-2025 09:00 AM

Ultimovacs ASA Gains Prospectus Approval

Ultimovacs ASA is making headlines with its recent developments aimed at enhancing its business landscape. The Company, known for its pioneering work in immunotherapies, has taken another significant step forward by obtaining approval for its prospectus, an important document that outlines details about its upcoming share listing.

Collaboration for Enhanced Growth

On February 28, 2025, Ultimovacs ASA announced an ambitious Business Combination with Zelluna Immunotherapy AS. This merger is strategically designed to bolster their capabilities and expand their market offerings. The agreement is expected to lead to synergies that will provide greater value to both companies and their stakeholders.

Private Placement Shares and Business Combination

As part of this Business Combination, Ultimovacs is set to issue 147,991,521 Consideration Shares and 19,873,071 Private Placement Shares. Each of these shares carries a nominal value of NOK 0.10. This share issuance is pivotal for the merger as it lays the foundation for the Company's expansion efforts post-M&A activities.

Public Disclosure and Trading Information

In conjunction with the Business Combination, the Company’s prospectus has received the green light from Norway's Financial Supervisory Authority. Following this approval, the prospectus will be accessible to the public, allowing potential investors and interested parties to familiarize themselves with the forthcoming trading conditions of the Consideration Shares and Private Placement Shares.

Date of Trading Launch

The anticipated first day of trading for these shares is projected to be around March 4, 2025. Though contingent upon the successful conclusion of their Business Combination, this date generates excitement for investors looking to be part of Ultimovacs' growth trajectory.

Looking Ahead: A Promising Future

With the prospectus approval, Ultimovacs ASA is positioning itself for a segment of growth that could significantly influence its market presence. Investors are encouraged to monitor developments closely as the listing date approaches. The Company remains committed to providing transparency and updates throughout this crucial period.

Contacting Ultimovacs for Inquiries

For those seeking additional information, Ultimovacs encourages interested parties to reach out directly. Investors can contact Hans Vassgård Eid, CFO and Interim CEO, via email at hans.eid@ultimovacs.com or by phone at +47 482 48632.

Frequently Asked Questions

What is the significance of Ultimovacs' prospectus approval?

Approval of the prospectus marks a crucial milestone for Ultimovacs as it prepares for new share listings essential for growth following its business combination.

When will the trading for new shares begin?

Trading for the shares is expected to start on or about March 4, 2025, dependent on the successful completion of the Business Combination.

How many shares will Ultimovacs issue during the combination?

Ultimovacs plans to issue a total of 167,864,592 shares, consisting of both Consideration and Private Placement Shares.

Who can I contact for more information about Ultimovacs?

You can reach out to Hans Vassgård Eid by email at hans.eid@ultimovacs.com or by phone at +47 482 48632 for further inquiries.

What is Ultimovacs known for?

Ultimovacs ASA specializes in developing innovative immunotherapies aimed at treating cancer, contributing significantly to advancements in this critical field.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.